EirGenix, Inc.

Industry

  • Contract Manufacturing Organization
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
      • Antibodies
See more in Biomedtracker

Latest on EirGenix, Inc.

Generics Bulletin

Sandoz Looks To Join EU Trastuzumab Party With CHMP Thumbs Up

 
• By Dean Rudge

Sandoz’s four-year old pact with EirGenix, Inc. handing the firm near global rights to the Taiwanese developer’s trastuzumab biosimilar has come to fruition, with the European Medicine Agency’s Com

Generics Bulletin

EirGenix Looks For Partner As Pertuzumab Passes Phase I

 
• By Dave Wallace

As EirGenix announced that its second breast cancer biosimilar, its EG1206A proposed rival to Perjeta (pertuzumab), had successfully completed a European Phase I trial, the Taiwanese developer made

Generics Bulletin

Sandoz Files US Trastuzumab With EirGenix

 
• By Dave Wallace

Sandoz has delivered on its partnership with EirGenix for a biosimilar rival to Herceptin (trastuzumab) by filing a biologics license application for the product with the US Food and Drug Administr

Generics Bulletin

Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount

 
• By Vibha Ravi

In a significant milestone, Zydus Cadila has launched in India the world’s first biosimilar to Roche ’s Kadcyla (trastuzumab emtansine), used to treat early and metastatic human epidermal growth fa